British drugmaker GSK said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of its oral therapy to treat anaemia in patients with a type of bone marrow cancer called myelofibrosis. A decision on the registration of myelofibrosi is expected by early 2024, GSK said in a statement.